Archive for January, 2008
January 19th, 2008. Tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in adenocarcinoma pleural effusions
0%. In conclusion, immunocytochemical detection of TIMP-2 could be considered an interesting marker in metastatic adenocarcinoma pleural effusions, and could possibly be used as a component of an antibody panel in diagnostic cytopathology.
January 18th, 2008. Primary malignant mesothelioma of the abdominal wall: complete response with radiotherapy alone
She had a complete response with no evidence of local progression when two years after treatment imaging revealed lung metastases, confirmed on biopsy. The present case suggests that radiotherapy alone can provide sustained local control of mesothelioma.
January 18th, 2008. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry
2, WT1, and AE1/AE3 is recommended for routine pathological diagnosis. Accurate clinical information is necessary for differentiating sarcomatoid mesothelioma from sarcomatoid carcinoma.
January 18th, 2008. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study
The combination of 8OHdG, VEGFβ, and SMRPs best distinguished the individual groups, suggesting a potential indicator of early and advanced MM cancers. The combination of blood biomarkers and radiographic findings could be used to stratify the risk of mesothelioma in asbestos-exposed populations.
January 17th, 2008. Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure
Conclusions: Environmental exposure to asbestos begins at birth and this may be important in the age of disease onset, if a threshold model for cancer initiation is operative. Both men and women had an excess risk of mesothelioma. Given that a family history of MPM was not common in this relatively homogenous patient group, a genetic predisposition to mesothelioma appears unlikely.
January 16th, 2008. Anesthetic management of patients undergoing extrapleural pneumonectomy for mesothelioma
This review summarizes relevant surgical aspects and anesthetic insights from the Brigham and Women's Hospital experience. Included are the anesthetic implications of intraoperative intracavitary hyperthermic chemotherapy in combination with extrapleural pneumonectomy - an emerging therapeutic option in the treatment of malignant pleural mesothelioma.
Posted in Chemotherapy, Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Intrapleural Chemotherapy, Pleural, Pleurectomy/decortication, Surgery, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 12th, 2008. Twenty-five years of fiber analysis: what have we learned?
The decrease in asbestos body and amosite concentrations over time is consistent with the banning of asbestos from insulation products in 1972. The source for the increased detection of crocidolite was not identified and needs further investigation.
January 12th, 2008. Helical Tomotherapy : Experiences of the First 150 Patients in Heidelberg
Conclusion: Helical tomotherapy and daily image guidance with MV-CT could fast
January 11th, 2008. Cytologic malignancy versus benignancy: how useful are the “newer” markers in body fluid cytology?
Conclusions: MOC-31 and D2-40 were very sensitive and specific markers of epithelial and mesothelial cells, respectively. Compared with calretinin, D2-40 was a more sensitive marker of mesothelial cells. WT1 proved to be nonspecific. XIAP was not a sensitive marker for malignancy and had a limited value in cytology. We recommend using a panel to include MOC-31 and D2-40 to improve diagnostic accuracy in body cavity effusions.
January 9th, 2008. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis.
Conclusions: IPHP is a safe treatment modality for patients with peritoneal carcinomatosis. It has an acceptable complications rate and ensures a marked improvement in survival and in the quality of life in selected patients.
January 9th, 2008. Early cytological diagnosis of diffuse malignant mesothelioma of the peritoneum: A case report
Routine cytology supported by three adjuvant methods enabled us to correctly establish the diagnosis. Our case suggests that a cytological diagnosis of malignant mesothelioma supported by adjuvant methods should not be rejected even if based on negative histological results.
January 8th, 2008. Presence of malignant mesothelial cells in the sputum
We report a rare case in which malignant pleural mesothelioma cells were found in the sputum. For the differential diagnosis of a mass involving both the pleura and lung, physicians should consider that malignant mesothelial cells can be found in the sputum, although this is very rare.
January 4th, 2008. Environmental mesothelioma associated with tremolite asbestos: Lessons from the experiences of Turkey, Greece, Corsica, New Caledonia and Cyprus
It can also elucidate the effects of fibers that behave like amphibole asbestos. However, this type of exposure is not useful for studying the potential effects of small amounts of asbestos in the ambient air of big cities due to the differing nature of the fiber types and modes of exposure between the regions.
January 3rd, 2008. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells
In addition, a splice variant transcript of mesothelin (variant 3) was detected in these MPM cell lines, in accordance with the release of a secreted part of the protein. Our results indicate that both mechanisms could be implicated in soluble mesothelin production by epithelioid mesothelioma cells.
January 2nd, 2008. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy
Conclusion: This new approach combining complete cytoreductive surgery considerably increases the survival of patients with MPM compared with the standard treatment based on systemic chemotherapy.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Oxaliplatin (Eloxatin), Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 2nd, 2008. Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic
In 2007, a more aggressive therapeutic approach is becoming common practice with the use of radiotherapy and the emergence of the concept of multimodal care centered on wide pleuropneumonectomy. These advances create real hope for improvement, but also many interrogations since no standard treatment protocol has been clearly identified.
Posted in Epidemiological, Extrapleural Pneumonectomy (EPP), Full Archive, General, Pleural, Pneumonectomy, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 1st, 2008. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients
Conclusions: Significant predictors of survival include performance status, platelet count, histology, and degree of involvement of pleural cavity. Within the confines of this retrospective study and the small number of patients undergoing multimodality therapy, the role of surgery in the treatment of MPM remains unclear. Further investigation is warranted to determine the optimal treatment strategy in this disease.
|
|  |
